Navigation Links
Zafgen Secures $21 Million in Series D Financing
Date:12/4/2012

CAMBRIDGE, Mass., Dec. 4, 2012 /PRNewswire/ -- Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced it has secured $21 million in a Series D equity financing. New investor, Alta Partners, a prominent venture capital firm in life sciences, leads the financing, joining existing investors Atlas Venture and Third Rock Ventures. Proceeds from the financing will be used to support the continued development of beloranib, the obesity therapeutic that is currently in phase 2a clinical development.

"We are thrilled to have attracted more world-class investors to our syndicate as we move forward with phase 2a clinical testing for beloranib," said Thomas Hughes, Ph.D., president and chief executive officer, Zafgen, Inc. "Alta Partners has a strong portfolio and consistent track record of recognizing and investing in high-growth firms.  We appreciate their confidence in the promise of beloranib to help address the unmet needs of severely obese patients."  

Beloranib utilizes a unique mechanism of action targeting Methionine Aminopeptidase 2 (MetAP2). The therapeutic is in development to assess potential to safely and rapidly reduce body weight by restoring balance between the production and utilization of fat.

On November 6, 2012, Zafgen announced the initiation of Phase 2a clinical testing of beloranib following the completion of three consecutive Phase 1b studies demonstrating rapid weight loss, reductions in body fat, improvements in cardiovascular risk factors and encouraging tolerability. The phase 2a clinical trial will evaluate weight loss, safety and pharmacokinetics of beloranib administered twice a week. Results from this study are anticipated to be available in June, 2013. 

"We are impressed with Zafgen's leadership and efficient business approach and encouraged by early results with beloranib," said Ed Hurwitz, director a
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
2. Delcath Systems, Inc. Secures $20 Million Credit Facility
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Benvenue Medical Secures $25 Million Series D Financing
5. PLC Systems Secures Additional Financing For US Clinical Trials And General Working Capital
6. Dr. Jills Foot Pads Secures GSA Schedule and Expands to Service VA and Federal Agencies
7. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
8. BioMotiv Secures $21 million in Initial Funding
9. ROX Medical secures financing and achieves key milestones in providing minimally-invasive approach for treating hypertension
10. Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team
11. Flexion Therapeutics Secures $20 Million in Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  MedScope ( www.medscope.org ), ... nominated for a 2015 Connected World magazine ... Response System (mPERS), that can be used anywhere, anytime. ... partner.  In nominating MedScope, Landon ...
(Date:1/23/2015)... all-time hits leader, is the new spokesperson for the topical ... announced. "Pete,s a Hall of Famer in our ... with Myoflex," said Ducere Pharma Chief Executive Officer Chris ... across all generations. The passion and intensity that Pete brought ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
(Date:1/22/2015)... a new blog post presenting a list of vehicles that cannot ... Some types of vehicles cannot be covered under an ordinary auto ... see if their vehicle qualifies for auto insurance coverage. , ... that cannot be covered by a plan. Clients have little options ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Step into ... at the Science Museum of Virginia. Wicked Plants, the ... Wicked Plants unearths 75 poisonous, carnivorous and diabolical plants ... each room to uncover the biochemical, physical and neurological ...
(Date:12/26/2014)... December 26, 2014 The US represents the ... report. In 2013, GlobalData’s forecast estimates that sales of branded ... market due to the high incidence of the disease, high ... 5EU, Japan, and China. Increased sales of CRC therapies over ...
Breaking Medicine News(10 mins):Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... class of breast cancer drugs, worked better than standard ... with advanced disease. Femara is a member of a ... differently to prevent certain kinds of breast cancer than ... better and helped more women survive. The US Food ...
... other vascular diseases are the leading causes of ... depiction of stenotic, occlusive, aneurismal, inflammatory or vascular ... are used to depict vascular lesions with high ... It is the gold standard with a very ...
... used in vitro fertilisation (IVF) technique intracytoplasmic sperm injection ... with abnormalities such as ambiguous genitalia. Researchers from the ... infertility is genetic are likely to have other, more ... spermatozoa are injected directly into the egg. // ...
... might overcome a major obstacle to treating brain ailments ... in rats, researchers from the Stroke Lab and Alzheimer's ... direct path from the nose to the brain” could ... foreign substances, including drugs. ,Senior investigator Dr. William ...
... The use of refined fossil fuels--especially kerosene, which is ... source--may cause sniffling, wheezing, itching, and other allergy symptoms. ... the fuels may somehow irritate the nasal lining and ... // ,The researchers studied the effects of ...
... out why women who have a baby when they are ... They have identified a substance produced naturally in the body ... the changes in the breast tissue of young women. The ... that could protect against breast cancer. ,In experiments, ...
Cached Medicine News:Health News:Magnetic resonance angiography in clinical medicine 2Health News:Nasal Spray Could Take Drugs Directly to Brain 2
Barraquer needle holder, curved, delicate....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Rhoton #12 straight point needle semisharp, titanium....
Micro 2000, micro scissors micro 2000 supercut....
Medicine Products: